ZTS · 8-K · 20261105PR000048

Restructuring Charges

Zoetis Inc. · 2026-11-05 · Importance 71 · Surprise 82 · From source text

Restructuring charges and certain acquisition and divestiture-related costs were $43 million in the third quarter of 2026, compared with $4 million a year earlier. For the nine months ended September 30, 2026, those charges totaled $142 million, versus $34 million in the prior-year period. The company reported $125 million of other restructuring charges and cost-reduction/productivity initiatives for the nine-month period, primarily employee termination costs under a comprehensive cost and productivity program and additional organizational refinements. The release also disclosed $89 million in certain asset impairment charges, including impairment of PetMedix in-process research and development assets and charges related to site exits.

Key facts

• Zoetis Inc. reported third-quarter 2026 restructuring charges and certain acquisition and divestiture-related costs of $43 million, compared with $4 million a year earlier. source
• Zoetis Inc. reported $30 million of other restructuring charges and cost-reduction/productivity initiative costs in the third quarter of 2026 and $125 million for the first nine months of 2026. source
• Zoetis Inc.'s 2026 restructuring and cost-reduction/productivity initiative costs were primarily driven by employee termination costs under a comprehensive cost and productivity program; the nine-month period also included termination costs from additional organizational structure refinements. source

Impact estimates